We are live on
!
Find out more
B
Bellecapital Portfolio holdings
AUM
$625M
1-Year Est. Return
39.69%
This Fund
S&P 500
This Quarter
Est. Return
+5.95%
1 Year Est. Return
+39.69%
3 Year Est. Return
+127.77%
5 Year Est. Return
+155.51%
10 Year Est. Return
+530.97%
AUM
$114M
AUM Growth
+$5.96M
(+5.5%)
Cap. Flow
+$1.42M
Cap. Flow
% of AUM
1.24%
Top 10 Holdings %
Top 10 Hldgs %
48.81%
Holding
78
New
3
Increased
13
Reduced
18
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$5.07M |
| 2 |
WisdomTree Japan Hedged Equity Fund
DXJ
|
+$2.66M |
| 3 |
State Street SPDR S&P International Small Cap ETF
GWX
|
+$1.51M |
| 4 |
JD.com
JD
|
+$970K |
| 5 |
Alibaba
BABA
|
+$778K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$3.22M |
| 2 |
Cisco
CSCO
|
+$2.07M |
| 3 |
Pfizer
PFE
|
+$1.03M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$991K |
| 5 |
McKesson
MCK
|
+$851K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.97% |
| 2 | Consumer Discretionary | 16.41% |
| 3 | Healthcare | 15.86% |
| 4 | Communication Services | 14.66% |
| 5 | Technology | 12.25% |
Similar funds
TAM
RIP
CWM
LWP
FGA
BVC
APM
PIM
Bellecapital's Q2 2017 Portfolio in Review
As of Q2 2017, Bellecapital held 78 positions worth $114M, up 5.5% from $108M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Bellecapital's Q2 2017 filing shows 3 new, 13 increased, 18 reduced and 7 closed positions. Its largest new stake was PRA Health Sciences, Inc.: 73,180 shares worth $5.49M. The largest sale was Procter & Gamble, an estimated $3.22M.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Bellecapital's largest Q2 2017 buy was PRA Health Sciences, Inc.: 73,180 shares worth $5.49M.
- Bellecapital added most to WisdomTree Japan Hedged Equity Fund in Q2 2017, an estimated $2.66M increase.
- Bellecapital's biggest Q2 2017 reduction was Procter & Gamble, cutting an estimated $3.22M.
- Bellecapital fully exited Pfizer in Q2 2017, selling an estimated $1.03M.
- Bellecapital's ten largest holdings make up 49% of its $114M portfolio in Q2 2017.
- Bellecapital opened 3 new positions and closed 7 in Q2 2017.
- Bellecapital's portfolio value rose 5.5% quarter-over-quarter to $114M.
Based on Bellecapital's 13F filing for Q2 2017, filed 26 Jul 2017.